You just read:

Influx of TAF-Containing Fixed-Dose Combinations From Gilead and Janssen Will Address Patient Needs for Long-Term Safety and Replace Established Treatment Options in the HIV Market

News provided by

Decision Resources Group

29 Sep, 2016, 08:30 ET